ASND

Ascendis Pharma AS (ASND)

Ascendis Pharma AS

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ASND

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2025/01/13	07:00	GlobeNewswire Inc.	Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:ASND	Ascendis Pharma AS
2025/01/06	22:30	GlobeNewswire Inc.	Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:ASND	Ascendis Pharma AS
2024/12/31	06:04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ASND	Ascendis Pharma AS
2024/12/19	22:30	GlobeNewswire Inc.	YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults	NASDAQ:ASND	Ascendis Pharma AS
2024/12/17	20:04	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ASND	Ascendis Pharma AS
2024/12/16	22:30	GlobeNewswire Inc.	New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26	NASDAQ:ASND	Ascendis Pharma AS
2024/12/13	06:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ASND	Ascendis Pharma AS
2024/12/13	06:01	GlobeNewswire Inc.	FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency	NASDAQ:ASND	Ascendis Pharma AS
2024/12/12	06:03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ASND	Ascendis Pharma AS
2024/12/11	07:16	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/12/11	07:07	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/12/11	07:02	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/12/11	06:59	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/12/11	06:58	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/12/11	06:55	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/12/04	06:35	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/11/20	06:08	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ASND	Ascendis Pharma AS
2024/11/15	06:19	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ASND	Ascendis Pharma AS
2024/11/15	06:01	GlobeNewswire Inc.	Ascendis Pharma Reports Third Quarter 2024 Financial Results	NASDAQ:ASND	Ascendis Pharma AS
2024/11/15	03:28	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:ASND	Ascendis Pharma AS
2024/11/14	23:31	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:ASND	Ascendis Pharma AS
2024/11/14	06:02	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ASND	Ascendis Pharma AS
2024/11/08	06:01	GlobeNewswire Inc.	Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024	NASDAQ:ASND	Ascendis Pharma AS
2024/11/04	21:05	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ASND	Ascendis Pharma AS
2024/11/04	21:00	GlobeNewswire Inc.	Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases	NASDAQ:ASND	Ascendis Pharma AS
2024/10/10	05:01	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ASND	Ascendis Pharma AS
2024/09/30	21:35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ASND	Ascendis Pharma AS
2024/09/30	21:30	GlobeNewswire Inc.	New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024	NASDAQ:ASND	Ascendis Pharma AS
2024/09/30	21:30	GlobeNewswire Inc.	Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency	NASDAQ:ASND	Ascendis Pharma AS
2024/09/28	05:59	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:ASND	Ascendis Pharma AS